Related Experiment Video
Updated: Apr 5, 2026
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Novel HIV-1 Integrase Inhibitor Development by Virtual Screening Based on QSAR Models
Laura Guasch, Alexey V Zakharov, Olga A Tarasova
1CADD Group, Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Frederick, Frederick, MD 21702, USA. mn1@helix.nih.gov.
Computational methods were used to design novel HIV-1 integrase (IN) inhibitors. A validated quantitative structure-activity relationship (QSAR) model identified 236 potential drug candidates, with one compound showing experimental ST inhibition.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Virology
Background:
- HIV-1 integrase (IN) is essential for viral replication, integrating the virus into the host genome.
- Developing novel HIV-1 IN inhibitors is crucial for combating HIV/AIDS.
Purpose of the Study:
- To computationally design and identify novel inhibitors of HIV-1 integrase (IN).
- To develop and validate quantitative structure-activity relationship (QSAR) models for HIV-1 IN strand transfer (ST) inhibitors.
Main Methods:
- Collected experimental data to create an IN inhibitor database.
- Developed and validated QSAR models using cross-validation and an external dataset.
- Screened a combinatorial library and used docking to identify potential inhibitors.
Main Results:
- Identified 236 compounds with favorable druglikeness and docking poses.
- Synthesized six compounds, one of which inhibited the ST reaction with an IC50(ST) of 37 µM.
- The IN inhibitor database is publicly available for download.
Conclusions:
- Computational approaches, including QSAR and docking, are effective for designing novel HIV-1 IN inhibitors.
- The identified compounds represent promising leads for further drug development against HIV-1.
- The developed database and models can aid future research in HIV-1 IN inhibitor discovery.
